News

LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), the global leader in relapsed/refractory…

Analyses presented at ACC reinforce the totality of data for vutrisiran in patients with ATTR-CM including the impact on cardiovascular outcomes across a range of…

AbstractCrescentic renal amyloidosis is a rare complication of light-chain (AL) amyloidosis. We report the case of a 73-year-old man with AL amyloidosis involving…

 I would like to attend…Live In Person in New OrleansSaturday, March 28, 20266:30-7:00 AM CDT: Registration & Breakfast7:00-8:00 AM CDT: SymposiumVirtually…

BackgroundCardiac amyloidosis is an infiltrative cardiomyopathy characterized by restrictive physiology and progressive heart failure. Pericardial calcification is…

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like…

Fresh funding backs a high-stakes attempt to do what current amyloidosis drugs still cannot: clear the buildup already damaging the heart.UK-based biotech Immutrin…

The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge…

Amyloidosis is a rare disease involving the formation and spread of abnormal proteins in the body. Unlike with other proteins, the body cannot naturally recycle…

PurposeAmyloid positron emission tomography (PET) tracers are increasingly used to detect cardiac amyloidosis (CA). 11C-Pittsburgh compound B (PiB) and 1⁸F-…